Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Oct 2 - Oct 7
& Daly, A
Demand for GLP-1RAs has increased significantly in recent years [See Figure 1], driven primarily by their use for weight-loss purposes rather than for diabetes
PHASE 2 OBESITY TRIAL Triple-Hormone Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Published in the New England Journal of Medicine in 2023, this study reported substantial reductions in body weight across multiple dose groups and helped establish Retatrutide as one of the most closely followed compounds in obesity research
Therefore, the observed decrease in energy expenditure in our study is likely attributable not only to reduced food intake but also to reduced locomotor activity induced by GLP-1 analogs
US$ 28.78
US$ 28.62
US$ 21.69
